USE OF ANTI-VEGF DRUGS IN DIABETIC RETINOPATHY (LITERATURE REVIEW)

Authors

  • Normatova Nargiza Mirshovkatovna DSc, docent Center for the Development of Professional Qualifications of Medical Workers
  • Khamidullaev Firdavs Faridovich Samarkand State Medical University
  • Saidov Temur Tolibovich Samarkand State Medical University

DOI:

https://doi.org/10.17605/OSF.IO/ZHMFS

Keywords:

anti-VEGF drugs, diabetic retinopathy, endothelial cells, ophthalmology

Abstract

The treatment of diabetic retinopathy (DR) with modern conservative methods, the combination of which with standard therapy improves the long-term prognosis of the disease, is being actively developed and widely implemented. Today, tools that block vascular endothelial growth factor (VEGF), which is considered to be the main cause of the mechanism of neovascularization, as well as vascular hyperfiltration into the retina, have become widely available in practice. A detailed study of the properties of VEGF answers the question of the appropriateness of its use in patients with diabetes, its effectiveness, and the potential complications that could pose a serious threat to vision and health in general

Downloads

Published

2022-10-06

Issue

Vol. 3 No. 10 (2022): wos

Section

Articles